Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
35.03
+0.33 (+0.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Corcept Therapeutics
< Previous
1
2
3
4
5
Next >
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
August 03, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90...
Via
Benzinga
Earnings Preview For Corcept Therapeutics
August 01, 2023
Via
Benzinga
Analyst Expectations for Corcept Therapeutics's Future
May 26, 2023
Via
Benzinga
Corcept Therapeutics's Return On Capital Employed Overview
May 10, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023
April 11, 2023
Via
Benzinga
Short Volatility Alert: Corcept Therapeutics
April 05, 2023
On Tuesday, shares of Corcept Therapeutics (NASDAQ: CORT) experienced volatile short activity. After the activity, the stock price went up +1.66% to $22.02. The overall sentiment for CORT has been...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
April 04, 2023
Via
Benzinga
Analyst Ratings for Corcept Therapeutics
April 04, 2023
Via
Benzinga
Analyst Expectations for Corcept Therapeutics's Future
March 08, 2023
Via
Benzinga
Corcept Therapeutics Return On Capital Employed Overview
August 11, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
February 15, 2023
Via
Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
December 15, 2022
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
Corcept Therapeutics's Earnings: A Preview
November 02, 2022
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
These 3 Stocks Are Winning the Bear Market -- Here's How
October 21, 2022
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
Via
The Motley Fool
7 Under-the-Radar Stocks With 100% Upside Potential
October 17, 2022
If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully.
Via
InvestorPlace
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
July 26, 2022
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
August 01, 2022
Upgrades
Via
Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
July 15, 2022
The group has several commonalities, including strong ratings and promising charts.
Via
Investor's Business Daily
3 Biotech Stocks Outperforming a Bear Market
July 15, 2022
These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy.
Via
InvestorPlace
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
July 13, 2022
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.
Via
Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
July 11, 2022
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier.
Via
Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
July 11, 2022
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating.
Via
Investor's Business Daily
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
July 08, 2022
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.
Via
Investor's Business Daily
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
July 08, 2022
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier.
Via
Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
July 05, 2022
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.
Via
Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
June 30, 2022
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.
Via
Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
June 30, 2022
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
June 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
June 29, 2022
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.